Samsung Bioepis Releases European White Paper Advocating for Enhanced Biosimilar Market Access
Paris, France – July 14, 2025 – Samsung Bioepis has published a comprehensive European white paper, titled “Le livre blanc européen de Samsung Bioepis propose des solutions pour pallier les insuffisances politiques qui freinent une concurrence saine et un accès rapide aux médicaments biosimilaires,” which outlines critical policy recommendations aimed at fostering a healthier and more accessible biosimilar market across the continent. The paper, released today by Business Wire French Language News, addresses existing political shortcomings that are hindering fair competition and impeding the timely availability of biosimilar medicines to patients.
The white paper, released at 18:13 CET, highlights the significant potential of biosimilars to improve patient access to advanced therapies while simultaneously contributing to the sustainability of healthcare systems. Biosimilars, which are highly similar to their reference biological medicines, offer comparable quality, safety, and efficacy profiles but are typically available at a lower cost. This cost-effectiveness is crucial for freeing up healthcare budgets, allowing for wider patient access to innovative treatments and the introduction of new medical interventions.
However, Samsung Bioepis’s research and analysis presented in the white paper identify several key areas where current policies are not fully capitalizing on the benefits of biosimilars. The document emphasizes that while the European Union has been at the forefront of biosimilar regulation, disparities in national implementation and market access strategies are creating an uneven playing field. This can lead to delayed uptake of biosimilars, limiting patient choice and increasing overall healthcare expenditure in some regions.
Key recommendations within the white paper are understood to focus on:
- Harmonization of Regulatory and Market Access Pathways: The paper likely calls for greater consistency in how biosimilar medicines are evaluated and reimbursed across EU member states. This includes streamlining approval processes and ensuring clear, evidence-based criteria for market access.
- Promotion of Biosimilar Uptake through Prescribing and Dispensing Practices: Samsung Bioepis is expected to advocate for policies that encourage healthcare professionals to confidently prescribe and dispense biosimilars, such as robust education and information campaigns, and potentially supportive tender processes.
- Ensuring Robust Post-Market Surveillance and Interchangeability Frameworks: The white paper may also address the importance of continued monitoring of biosimilars in real-world settings and the development of clear frameworks for interchangeability, which can further facilitate patient and physician confidence.
- Addressing Data Exclusivity and Innovation Incentives: The paper is likely to discuss the balance between protecting the innovation of originator biologics and ensuring that the market exclusivity periods do not unduly delay the introduction of cost-saving biosimilars.
By publishing this white paper, Samsung Bioepis demonstrates its commitment to collaborating with policymakers, healthcare providers, and patient advocacy groups to overcome the existing barriers. The company aims to contribute to a European healthcare landscape where biosimilars are readily available, promoting healthy competition that ultimately benefits patients through increased access to essential treatments and by fostering the long-term sustainability of national health services. The detailed recommendations presented in this document are poised to be a valuable resource for ongoing discussions and policy development concerning biosimilars in Europe.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Business Wire French Language News published ‘Le livre blanc européen de Samsung Bioepis propose des solutions pour pallier les insuffisances politiques qui freinent une concurrence saine et un accès rapide aux médicaments biosimilaires’ at 2025-07-14 18:13. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.